MMMohini Mondal

Mohini Mondal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohini Mondal has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microplastics and gut dysbiosis: links to cancer inflammation

    by Joy Das, Utpal Bhui, Samy Selim, Sathvik Belagodu Sridhar, Ashok Kumar Sah, Anas Islam, Uttam Prasad Panigrahy, Shubhrajit Mantry, Mohd. Tariq, Biplab Debnath, et al.

  • Circular RNAs at the crossroads of oxidative stress: novel targets for precision therapeutics

    by Vijay Singh, Rashmi Sinha, Joy Das, Anas Islam, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, Shubhrajit Mantry, Haleema Shahin, Krishnendu Adhikary, Radheshyam Pal, et al.

  • Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review

    by Sumel Ashique, Mohini Mondal, Sadique Hussain, Anas Islam, Mohd Tariq, Dinesh Kumar Chellappan, Sabina Yasmin, Tabarak Malik, Juberahamad Rajjak Attar, Yousuf Ansari

    Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.

  • Open Access

    Emerging cases of Naegleria fowleri infection in India: A brief report (2018–2025)

    by Sumel Ashique, Mohini Mondal, Anas Islam, Sadique Hussain, Sathvik Belagodu Sridhar, Mohd Tariq, Tabarak Malik


  • Open Access

    The molecular landscape of kidney stone disease: pathophysiology to personalized intervention

    by Neha Sharma, Joy Das, Utpal Bhui, Biplab Debnath, Mohini Mondal, Rajarshi Nath, Nallapuraju Jahnavi, Shreya Chowdhury, Yogesh Shinde, Navneet Khurana, et al.

    Urolithiasis is a complex and multifactorial disease with rising global prevalence. Traditional management strategies primarily focus on symptom relief and surgical intervention. However, with advances in genomics, metabolomics, and imaging technologies, precision medicine is reshaping the diagnostic and therapeutic landscape of kidney stone diseases. This review explored the integration of genetic screening, individualized metabolic evaluation, and risk stratification to enable tailored treatment plans. We discuss the current and emerging approaches that align with the principles of precision medicine, including the identification of monogenic and polygenic risk factors, advanced imaging for stone composition, and targeted lifestyle or pharmacological interventions. These developments herald a paradigm shift in urolithiasis care, moving beyond reactive treatment toward proactive, patient-specific management.

  • ROS-Mediated Cellular Signaling in Metabolic Disorders

    by Mohini Mondal, Sanket Pramanik, Mineshkumar Patel, Ankit Diwan, Ranit Kumar Samanta, Shubham Panja, Arpan Maity, Raj Pramanik

  • Phytomicronutrients in neurodegeneration: modulating microglial dynamics for neuroprotection

    by Krishnendu Adhikary, Gari Prameela, Joy Das, Mohhammad Ramzan, Krishnendu Ganguly, Nilanjana Datta, Pradipta Banerjee, Saurav Barman, Sathvik Belagodu Sridhar, Tahreen Taj, et al.

    Microglial dysfunction plays a critical role in the pathophysiology of several neurodegenerative diseases, including multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. Emerging evidence suggests that targeting microglial activation could be a promising therapeutic strategy. This review critically examines recent studies investigating the effects of medicinal plant extracts and their bioactive compounds on microglial function. Relevant data from experimental and preclinical studies were analyzed to assess their neuroprotective and anti-inflammatory potential. Phytochemicals that are found in plants, especially flavonoids, alkaloids, and terpenoids, demonstrate important modulatory effects on microglials. These compounds control microglial polarization, inhibit the release of proinflammatory cytokines, and alleviate oxidative stress, thus, alleviating neuroinflammation and enhancing neuro-restoration. The results suggest that medicine plant extracts have effects on major molecular pathways associated with neuroinflammation, which provide new adjunctive treatment to neurodegenerative diseases. Nevertheless, there are still problems in the translation of these preclinical successes into clinical practice. The limited bioavailability, variability in phytochemical composition, and the absence of standardized formulations are some of the challenges that discourage clinical use. Also, thorough safety assessments should be conducted to achieve therapeutic effectiveness with no adverse effects. The medicinal plants and their bioactive compounds hold potential promise in regulating the dysfunction of microglia and in decreasing neuroinflammation. Future studies are needed to enhance the pharmacokinetic characteristics, to provide consistency in formulations, and to perform stringent clinical studies that would substantiate these findings and allow their use in therapeutic regimens of neuroinflammatory disorders.


  • Oleosomes as emerging Next-Generation carrier for topical drug delivery

    by Sumel Ashique, Biplab Debnath, Shayeri Chatterjee Ganguly, Piyali Khamkat, Priya Manna, Sadique Hussain, Mohini Mondal, Tahreen Taj, Hitesh Chopra, Sabina Yasmin, et al.


  • Targeting mtDNA to Modulate Mitochondrial Dysfunction in Neurodegenerative Diseases

    by Sanket Pramanik, Biplab Debnath, Aganta Chakraborty, Anas Islam, Shrabasti Mullick, Priya Chaudhary, Rajarshi Nath, Dinesh Kumar Chellappan, Mohini Mondal, Sumel Ashique

    Mitochondrial dysfunction is a common pathological feature of neurodegenerative diseases namely Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. Although these disorders are primarily driven by disease-specific genetic and proteopathic mechanisms, increasing evidence suggests that secondary mitochondrial DNA (mtDNA) damage and heteroplasmy shifts may exacerbate bioenergetic failure and neuronal vulnerability. Distinguishing primary disease mechanisms from downstream mtDNA alterations is critical to accurately evaluate emerging therapeutic strategies. Recent advances in mtDNA-targeted genome editing have enabled the direct manipulation of mitochondrial genomes. Mitochondrially targeted zinc finger nucleases and TALENs can selectively alter mutant mtDNA to induce heteroplasmy shifts, whereas DddA-derived cytosine base editors allow precise base editing without double-strand breaks. However, each platform has distinct limitations related to the target scope, off-target risk, design complexity, and delivery efficiency. The application of CRISPR/Cas-based systems to mammalian mtDNA remains constrained by the unresolved challenges in guiding RNA import. This review critically examines mitochondrial dysfunction and mutant mtDNA accumulation in neurodegenerative diseases. It also evaluates current and emerging mtDNA-editing techniques, and highlights key translational barriers. We highlighted that mtDNA-targeted interventions can be a promising approach for disease-modifying or adjunctive strategies, rather than curative approaches. Graphical Abstract

  • Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment

    by Shrabasti Mullick, Aganta Chakraborty, Pratyush Porel, Rajarshi Nath, Priya Chaudhary, Anas Islam, Joy Das, Sanket Pramanik, Uttam Prasad Panigrahy, Sathvik Belagodu Sridhar, et al.

    Cognitive impairment (CI) and accelerating neuronal deterioration are hallmarks of amyotrophic lateral sclerosis (ALS). Under these circumstances a crucial molecular mechanism in the pathophysiology of CI has been identified: the CXC chemokine receptor type 7 (CXCR7)/CXC chemokine receptor type 4 (CXCR4)/Cysteine-X-cysteine chemokine ligand 12 (CXCL12) region. Research on ALS shows that the CXCR7/CXCR4/CXCL12 complex plays a role in the degeneration of motor neurons and the resulting cognitive decline. JAK/STAT, PI3K/AKT, MAPK, and other signaling pathways are among the ways the axis controls neuronal inflammation, synaptic remodeling, and neuronal maintenance in each of these scenarios. The CXC motif chemokine ligand 12 (CXCL12) and CXC chemokine receptor type 4 (CXCR4) axis is crucial for the start of the inflammatory mechanism because of their function in mediating the chemotaxis of inflammatory cells. By preventing the migration of inflammatory cells via CXCL12 in the inflammatory area, the response to inflammation can be prevented or reduced. Consequently, the development of CXCR4 antagonists has emerged as a cutting-edge strategy for inflammation treatment. Recent research suggests that managing this relationship could reduce cognitive deficits and offer neuroprotective benefits. According to the current review, the CXCL12/CXCR4/CXCR7 pathway may be a promising target for treating cognitive dysfunction in neurodegenerative disorder. It also emphasizes the need for additional research to completely comprehend its function and identify efficient treatments which may result in improved clinical treatment modalities for these debilitating illnesses. Graphical Abstract